Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $21.25 Consensus PT from Analysts

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been given an average recommendation of “Buy” by the six research firms that are covering the firm, MarketBeat.com reports. Six research analysts have rated the stock with a buy rating. The average 1 year target price among brokers that have updated their coverage on the stock in the last year is $21.00.

Several analysts have commented on the stock. Needham & Company LLC restated a “buy” rating and set a $23.00 price objective on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. HC Wainwright began coverage on shares of Artiva Biotherapeutics in a report on Monday, December 30th. They set a “buy” rating and a $20.00 target price for the company.

Institutional Investors Weigh In On Artiva Biotherapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. BNP Paribas Financial Markets acquired a new position in shares of Artiva Biotherapeutics in the 3rd quarter valued at $42,000. MetLife Investment Management LLC purchased a new position in Artiva Biotherapeutics in the third quarter valued at $135,000. JPMorgan Chase & Co. acquired a new position in shares of Artiva Biotherapeutics in the third quarter worth about $166,000. Barclays PLC purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter worth about $304,000. Finally, Charles Schwab Investment Management Inc. acquired a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $623,000.

Artiva Biotherapeutics Stock Up 7.0 %

Shares of ARTV stock opened at $10.67 on Monday. The stock has a fifty day moving average price of $11.37. Artiva Biotherapeutics has a 1 year low of $9.68 and a 1 year high of $17.31.

Artiva Biotherapeutics (NASDAQ:ARTV) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.68) by ($0.24). Analysts forecast that Artiva Biotherapeutics will post -4.68 EPS for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.